Antithrombotic Therapy After Transcatheter Aortic Valve Replacement: An Overview.

Mathew N Hindi, Mariama Akodad, Thomas Nestelberger, Janarthanan Sathananthan

Open access · goldAbstract readReview

In one paragraph

Review in Structural heart : the journal of the Heart Team, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

1.1field-weighted citation impact, top 20% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

Editorial: Antiplatelet Therapy Post-Transcatheter Aortic Valve Replacement - Less Is More but Is There a Better Option Than Aspirin?Structural heart : the journal of the Heart Team · 2023
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Mathew N HindiCentre for Cardiovascular and Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.

Mariama AkodadCentre for Cardiovascular and Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.

Thomas NestelbergerCentre for Cardiovascular and Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.

Janarthanan SathananthanCentre for Cardiovascular and Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.

University of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transcatheter aortic valve replacement (TAVR) is an established procedure for the treatment of patients with severe aortic stenosis. The optimal antithrombotic regimen following TAVR, currently unknown and inconsistently applied, is impacted by thromboembolic risk, frailty, bleeding risk, and comorbidities. There is a quickly growing body of literature examining the complex issues underlying antithrombotic regimens post-TAVR. This review provides an overview of thromboembolic and bleeding events following TAVR, summarizes the evidence regarding optimal antiplatelet and anticoagulant use post-TAVR, and highlights current challenges and future directions. By understanding appropriate indications and outcomes associated with different antithrombotic regimens post-TAVR, morbidity and mortality can be minimized in a generally frail and elderly patient population.

Indexed as

Antiplatelet therapyAntithrombotic therapyOral anticoagulationTranscatheter aortic valve replacement

Identifiers

PMID37288058

DOI10.1016/j.shj.2022.100085

PMCPMC10242582

OpenAlexW4296125871

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.